Credit Suisse Downgrades AbbVie On Humira Competitive Concerns

AbbVie Inc (NYSE: ABBV)'s stock is up 51 percent year-over-year, but its lifeblood may be draining.

The Rating

Credit Suisse analysts Vamil Divan and Michael Morabito downgraded AbbVie to Underperform and lowered their price target from $104 to $89.

The Thesis

The analysts attribute AbbVie’s run to Humira legal settlements and tax reform coupled with high pipeline expectations.

“The first two points have played out but we see pipeline enthusiasm now being stretched, at best limiting room for further upside over the next 12 months,” Divan and Morabito wrote in a note.

They identify long-term fundamental concerns, particularly with emerging competition limiting Humira’s longevity.

The fourth-quarter entry of biosimilars in Europe is seen to catalyze “rapid erosion” of Humira sales, while U.S. earnings are to be stunted by impending biosimilar competition, decreased ability for AbbVie to increase prices, the impact of copay accumulator programs, and action to work around “rebate traps” ahead of rival emergence.

Price Action

AbbVie had popped 3.3 percent Wednesday to $102.92 on unrelated financing news.

Related Links:

Pharma M&A Picks Up Momentum

Novartis Gets Approval For Remicade Biosimilar In Europe

Latest Ratings for ABBV

May 2018	Credit Suisse	Downgrades	Neutral	Underperform
May 2018	BMO Capital	Maintains	Underperform	Underperform
Apr 2018	Morgan Stanley	Maintains	Equal-Weight	Equal-Weight

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

See more from Benzinga

• Allergan Looks To Sell Women's Health, Infectious Disease Businesses

• After Roseanne Blames Ambien For Tweet, Sanofi Says Sleep Aid's Side Effects Don't Include Racism

• TherapeuticsMD Announces FDA Approval Of IMVEXXY — For Real This Time

© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.